Effect of dipyridamole on myocardial reperfusion injury: A double-blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery

Clinical Pharmacology and Therapeutics
S El MessaoudiG A Rongen

Abstract

Dipyridamole reduces reperfusion-injury in preclinical trials and may be beneficial in patients undergoing coronary angioplasty, but its effect on patients undergoing coronary artery bypass grafting (CABG) is unknown. We hypothesized that dipyridamole limits myocardial reperfusion-injury in patients undergoing CABG. The trial design was a double-blind trial randomizing between pretreatment with dipyridamole or placebo. In all, 94 patients undergoing elective on-pump CABG were recruited between February 2010 and June 2012. The primary endpoint was plasma high-sensitive (hs-) troponin-I at 6, 12, and 24 hours after reperfusion. Secondary endpoints were the occurrence of bleeding, arrhythmias, need for inotropic support, and intensive care unit length of stay. Finally, 79 patients (33 dipyridamole) were included in the per-protocol analysis. Dipyridamole did not significantly affect postoperative hs-troponin-I (change in plasma hs-troponin I -3% [95% confidence interval -23% to 36%]; P > 0.1). Secondary endpoints did not differ between groups. Dipyridamole prior to CABG does not significantly reduce postoperative hs-troponin release.

References

Apr 1, 1989·The American Journal of Physiology·G H MöserA Deussen
Jan 1, 1989·Clinical Pharmacology and Therapeutics·D C GermanT D Bjornsson
Sep 1, 1985·Basic Research in Cardiology·S NeesE Gerlach
Feb 11, 1988·Nucleic Acids Research·S A MillerH F Polesky
Oct 1, 1994·Journal of Molecular and Cellular Cardiology·S M MoscaH E Cingolani
Mar 3, 1996·Journal of Chromatography. B, Biomedical Applications·E Schreiber-Deturmeny, B Bruguerolle
Jun 19, 1998·The American Journal of Cardiology·G A RongenJ S Floras
Jun 14, 2002·American Journal of Physiology. Heart and Circulatory Physiology·David A LiemDirk J Duncker
Sep 12, 2002·Expert Opinion on Therapeutic Targets·Keith E Suckling, Colin H Macphee
May 3, 2003·European Heart Journal·F RoquesS A M Nashef
Jul 3, 2003·Pflügers Archiv : European journal of physiology·Stephen A BaldwinJames D Young
Mar 6, 2004·Clinical Pharmacology and Therapeutics·Peter BijlstraGerard A Rongen
Apr 9, 2005·Journal of Applied Physiology·Niels P RiksenGerard A Rongen
Jul 9, 2005·Clinical Pharmacology and Therapeutics·Niels P RiksenGerard A Rongen
Aug 15, 2006·Journal of the American College of Cardiology·Niels P RiksenGerard A Rongen
Feb 3, 2007·Stroke; a Journal of Cerebral Circulation·Kimiko UmemuraKoichi Hiraga
Aug 21, 2007·Journal of the American College of Cardiology·Ellis F Unger
Mar 22, 2008·Stroke; a Journal of Cerebral Circulation·Dallit MannheimAmir Lerman
Sep 4, 2008·Circulation·Patrick W SerruysUNKNOWN Integrated Biomarker and Imaging Study-2 Investigators
Mar 20, 2009·Journal of Cardiovascular Pharmacology·Marta PaivaDerek M Yellon
Apr 11, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Patrick MeijerGerard A Rongen
Jul 17, 2010·American Journal of Therapeutics·Sreekanth Racherla, Rohit Arora
Feb 10, 2011·JAMA : the Journal of the American Medical Association·Michael J DomanskiMichael E Farkouh
Mar 7, 2012·Expert Review of Clinical Pharmacology·Niels P Riksen, Gerard A Rongen
Apr 23, 2013·American Journal of Physiology. Heart and Circulatory Physiology·Inge van den MunckhofDick H J Thijssen
Sep 18, 2014·Current Pharmaceutical Design·Hiroyuki Kinoshita

❮ Previous
Next ❯

Citations

Apr 27, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Jocelyn StockwellFrancisco S Cayabyab

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.